Resource title

An economic evaluation of universal vaccination against Hepatitis B virus

Resource image

image for OpenScout resource :: An economic evaluation of universal vaccination against Hepatitis B virus

Resource description

This report presents the results of an economic evaluation utilizing U.K. data, into a vaccination programme against Hepatitis B using a genetically engineered, yeast-derived vaccine, Engerix B. Cost-effectiveness ratios were calculated for four different programmes: an infant vaccination programme; a child vaccination programme; an adolescent vaccination programme; and a combined child and adolescent programme. For each programme, the number of annual cohorts vaccinated was varied from 1 to 25. The outcome was defined as incremental life years gained, and the results are reported as costs per incremental life-year gained. Benefits were calculated in both undiscounted and discounted forms. All costs were discounted. The discount rate used was 6%. All major epidemiological and cost assumptions were subjected to a sensitivity analysis. Baseline results with benefits discounted range from £188 015 to £301 365 per life year gained, depending on the duration of programme and vaccination strategy. With benefits undiscounted, the comparable range is from £5234 to £13 034.

Resource author

Resource publisher

Resource publish date

Resource language

en

Resource content type

Resource resource URL

http://eprints.lse.ac.uk/22452/

Resource license